See Why NanoViricides (NYSE: NNVC) is Topping Our Morning Watchlist—Take a Look While It’s Still Early

*Sponsored Krypton Street Announces NanoViricides, Inc. (NYSE: NNVC) is Back  In The Spotlight—After Moving Approximately 34% Since The  Last Time We Brought It To You! And Here’s Why NanoViricides, Inc. (NYSE: NNVC) is Back On Our Radar… Recent Market Recognition: NanoViricides, Inc. (NYSE: NNVC) Made An Approx. 50% Move In Less Than A Month, Highlighting A Strong Interest. Low Float and Market Cap: With A Market Cap Under $20M And Less Than 16M Shares In The Public Float, NanoViricides, Inc. (NYSE: NNVC) Has Potential For Significant Movements. Broad-Spectrum Technology: NanoViricides, Inc. (NYSE: NNVC) Uses Proprietary Nanoviricide® Technology To Target A Broad Range Of Vi-rus-es, Including Mutant Strains. NV-387 on Track for Phase 2 Trials: NV-387 Has Shown Strong Results In Preclinical Studies And Completed Phase 1 Trials, Moving Toward Phase 2 For Emerging Vi-rus-es. Emerging Health Crisis in Texas: NanoViricides, Inc. (NYSE: NNVC) Is Advancing NV-387, A Potential Solution For Combating This Escalating Situation. Critical Time for FDA Submission: NanoViricides, Inc. (NYSE: NNVC) Is Moving Forward With FDA Submissions For NV-HHV-101 And NV-387 Which Could Address Global Health Threats. Keep Reading to See Why We Have All Eyes on NanoViricides, Inc. (NYSE: NNVC) For This Morning… March 6, 2025 Dear Reader, Coming off of yesterday’s SaaS profile that moved approximately 49% in less than 24 hours, we need to shift our focus to one of my favorite sectors.  Biotech and pharma are some of the most exciting industries, where a single breakthrough can turn an under-the-radar company into a major market player overnight. When we brought this next profile to your radar last month on 2/4/2025, it made an approximate 34% move, from $1.16 on 2/10 to $1.55 on 2/20.  Now, with the growing concerns over the health crisis in Texas and the new developments in Alabama, NanoViricides, Inc. (NYSE: NNVC) is back at the top of our watchlist.  The CDC has reported being on the ground in Texas as the number of cases linked to a highly transmissible vi-rus grows to 159, raising alarms about the escalating situation.  Meanwhile, NanoViricides, Inc. (NYSE: NNVC) is advancing NV-387, a promising broad-spectrum anti-vi-ral treatment, which has already shown strong preclinical results and completed successful Phase 1 trials, with Phase 2 trials on the horizon. The urgency for solutions is higher than ever.  With the demand for effective treatments reaching a fever pitch, companies like NanoViricides, Inc. (NYSE: NNVC) are positioned to step up in a big way—but don't expect them to fly under the radar for too long. NanoViricides, Inc. (NYSE: NNVC) Makes An Approximate 50% Move in Less Than a Month… With a market cap under $20M and less than 16M shares available in the public float, NanoViricides, Inc. (NYSE: NNVC) could have the type of structure that has historically fueled explosive growth potential.  In fact, NanoViricides, Inc. (NYSE: NNVC) made an approximate 50% move in less than a month, going from $1.03 on 1/28/2025 to $1.55 on 2/20/2025. This relatively low number of shares in the float can amplify the potential for significant swings, especially if demand begins to shift, making NanoViricides, Inc. (NYSE: NNVC) one little-known company to keep an eye on.  Keep reading to see why NanoViricides, Inc. (NYSE: NNVC) topping our watchlist tomorrow morning. NanoViricides, Inc. (NYSE: NNVC) Advances NV-387 to Phase 2 as  Health Crisis in Texas Escalates Yesterday, NanoViricides, Inc. (NYSE: NNVC) issued a press release highlighting their innovative approach to addressing global health threats, including the ongoing health crisis in Texas.  This crisis, driven by a highly transmissible vi-rus, has raised significant global concern due to its heightened risk of spreading across populations.  The CDC has reported being on the ground in Texas as the number of cases grows to 159, raising alarms about the escalating situation. The company’s leading candidate, NV-387, is showing significant promise in preclinical studies.  It has demonstrated broad-spectrum anti-vi-ral properties, positioning it as a strong contender in the fight against rapidly mutating vi-rus-es.  Importantly, NV-387 has successfully completed Phase 1 clinical trials with no adverse events reported, setting the stage for Phase 2 trials focused on respiratory infections and emerging health threats. NanoViricides, Inc. (NYSE: NNVC)’s ability to develop treatments that effectively target vi-rus-es resistant to conventional methods has garnered attention.  The company is advancing its regulatory strategy and preparing for a potential FDA submission.  With continued progress in clinical trials and positive preclinical data, NanoViricides, Inc. (NYSE: NNVC) is getting closer to addressing critical public health needs. As health experts raise concerns about the spread of the current health crisis in Texas, NanoViricides, Inc. (NYSE: NNVC) is stepping up to the challenge, with NV-387 offering a potential solution for addressing ongoing global health concerns. New Vi-rus Sparks Global Alarm—NanoViricides, Inc. (NYSE: NNVC) Steps Up to Address Emerging Threats The World Health Organization has declared a new vi-rus a Public Health Emergency, with a highly concerning variant that is more transmissible and deadly, particularly to children.  Despite global attention, no approved treatment exists, especially as the vi-rus spreads beyond its origin. NanoViricides, Inc. (NYSE: NNVC) is tackling this growing threat with NV-387, a promising treatment that has shown strong potential in preclinical studies.  After completing Phase 1 trials with no adverse events, the company is preparing for Phase 2 trials to evaluate NV-387’s safety and efficacy against this emerging vi-rus strain. Positioning to Combat a Potential Pan-dem-ic In addition to addressing the evolving vi-rus, NanoViricides, Inc. (NYSE: NNVC) is also focusing on the looming threat of a deadly bird-transmitted influenza strain.  Rapid mutations in this strain could render current treatments like Tamiflu ineffective.  NV-387, however, mimics host-side features the vi-rus cannot alter, ensuring continued efficacy.  Preclinical studies have shown NV-387’s superior efficacy, particularly against the bird-origin strain. NV-387: A Game-Changer in Vi-rus Treatment NV-387’s unique mechanism sets it apart from conventional anti-vi-ral treatments. Developed during the global pan-dem-ic, NV-387 has proven highly effective in animal models against C19, RSV, influenza, and orthopox vi-ruses.  It outperformed existing treatments like Tamiflu, positioning it as a go-to treatment for multiple vi-rus-es, including the bird-origin strain. Phase 2 Clinical Trials: Critical Progress NanoViricides is ready to begin Phase 2 trials for NV-387, focusing on patients infected with the new vi-rus variant and expanding its use for respiratory vi-rus-es, including influenza.  The trials will begin with dose escalation and move to a larger cohort to compare NV-387’s efficacy to existing treatments.  NanoViricides, Inc. (NYSE: NNVC) hopes to complete the trials within the year, potentially bringing a life-saving treatment to market by 2026. The Urgency of the Situation With no approved treatments for the dangerous new vi-rus variant and growing concerns over the bird-origin strain, NanoViricides, Inc. (NYSE: NNVC)’s research is crucial.  NV-387’s potential to prevent widespread infection and offer a cure is a beacon of hope for individuals worldwide.  With proven success in animal studies and ongoing clinical trials, NV-387 could play a pivotal role in addressing major global health threats. With $10B Market Potential, NanoViricides, Inc. (NYSE: NNVC) Eyes Major Breakthrough NanoViricides, Inc. (NYSE: NNVC) is a leader in developing nanomedicine dr-ugs to target vir-uses using its nanoviricide® technology.   This technology mimics host cell receptors to trick vir-uses into binding to the nanoviricide, dismantling them and blocking reinfection, providing a more durable solution than traditional antibodies or vax's. Key points: FDA Progress: Moving toward FDA submission with positive feedback on its NV-HHV-101 dr-ug candidate for herpes vir-uses. Innovative Technology: Nanoviricides can target vir-uses even as they mutate, offering broad protection against Vir-al infections. Manufacturing Facility: The company owns a cGMP-certified facility in Shelton, CT, allowing it to produce dr-ugs in-house, saving time and costs. HerpeCide™ Program: Focused on treating shingles, cold sores, and genital ulcers, with an estimated market size exceeding $10B. Diverse Pipeline: dr-ugs in development for influenza, HIV, Dengue, and Ebola with promising animal model results. Strong IP Portfolio: Exclusive patents for its TheraCour® technology, securing competitive market space. NanoViricides, Inc. (NYSE: NNVC) is positioned for growth with its breakthrough technology, broad pipeline, and in-house manufacturing, making it a key player in the fight against Vir-al diseases. 7 Reasons Why NanoViricides, Inc. (NYSE: NNVC) Topping Our  Watchlist This Morning… 1. Recent Market Recognition: NanoViricides, Inc. (NYSE: NNVC) made an approximate 50% move in less than a month, highlighting strong interest and positioning the company as one to watch in the biotech space. 2. Low Float and Market Cap: With a market cap under $20M and fewer than 16M shares in the public float, NanoViricides, Inc. (NYSE: NNVC) has the potential to witness significant swings if demand begins to shift. 3. Broad-Spectrum Technology: NanoViricides, Inc. (NYSE: NNVC) uses its proprietary nanoviricide® technology to target a wide range of vi-rus-es, including those that have proven resistant to traditional treatments, positioning it as an emerging player in the anti-vi-ral space. 4. NV-387 on Track for Phase 2 Trials: NV-387 has demonstrated strong results in preclinical studies and completed successful Phase 1 trials, paving the way for Phase 2 trials targeting emerging and respiratory vi-rus-es. 5. Addressing the Health Crisis in Texas: The growing number of cases linked to a transmissible vi-rus in Texas has heightened global concerns, and NanoViricides, Inc. (NYSE: NNVC) is advancing NV-387, a potential solution for combating this escalating situation. 6. Potential Solution for Mutating Vir-uses: The broad-spectrum nature of NV-387 gives it an edge over existing anti-vi-ral treatments, which may become less effective as vi-rus-es mutate, addressing the growing need for adaptable solutions. 7. Critical Time for FDA Submission: NanoViricides, Inc. (NYSE: NNVC) is moving forward with plans for FDA submission, with NV-HHV-101 and NV-387 positioned to address pressing global health threats in the near future. Consider Adding NanoViricides, Inc. (NYSE: NNVC) To Your Radar This Morning… NanoViricides, Inc. (NYSE: NNVC) is back in the spotlight after making an approximate 34% move since the last time we profiled it.  With a market cap under $20M and fewer than 16M shares in the public float, this biotech gem has the potential to see some serious action if demand picks up.  NanoViricides, Inc. (NYSE: NNVC) is making headlines with its innovative NV-387, a broad-spectrum treatment that’s already shown strong promise in preclinical studies and Phase 1 trials.  And with Phase 2 trials coming up, the company is gearing up to tackle some of the most pressing health threats today. The growing health crisis in Texas, fueled by a transmissible vi-rus, has the world’s attention. NanoViricides, Inc. (NYSE: NNVC) is advancing NV-387, a potential solution to combat this growing situation and others like it.  With its technology that adapts to mutating vi-rus-es, NanoViricides, Inc. (NYSE: NNVC) is positioning itself to address evolving threats that current treatments can’t keep up with. We have all eyes on (NNVC) this morning.  Consider taking a look at (NNVC) while it’s still early.  And—please keep an eye out for my next update. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/03/2025 and ending on 03/06/2025 to publicly disseminate information about (NNVC:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid fourteen thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (NNVC:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/nnvc/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice